ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the
London, May 6, 2021 - (ACN Newswire) - On March 28, FMC-Film Music Contest 2021 the unique international music competition and awards and one of the largest competitions of its kind in Europe expanding